🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)Has anyone dealt with semaglutide cardiovascular benefit: select trial deep dive?

Has anyone dealt with semaglutide cardiovascular benefit: select trial deep dive?

newstart_MO Sun, Dec 21, 2025 at 7:10 PM 10 replies 946 viewsPage 1 of 2
newstart_MO
New Member
12
45
Feb 2026
Springfield, MO
Dec 21, 2025 at 7:10 PM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Relative versus absolute is the distinction that gets lost: a 20% relative reduction on a high baseline risk is a large absolute benefit, and the same relative figure on a low baseline risk is a small one.

What I actually want to know is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

I would rather have one careful answer than five confident ones.

11 6bri_stats, pete_manc_UK, anna.melb_AU and 8 others
Reply Quote Save Share Report
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Dec 21, 2025 at 9:10 PM#2

Taking the question as asked, rather than the general version of it. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

Last edited: Dec 22, 2025 at 3:10 AM
10 5ZaraB_AL, JakeSmashed95, NauseaFreeNow and 7 others
Reply Quote Save Share Report
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Dec 21, 2025 at 11:10 PM#3
amsterdam_pete said:
The dose-response is real but shallow at the top.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

Last edited: Dec 22, 2025 at 12:10 AM
9 4adam_van, Dr.SurgeonPGH, rachel_ABQ and 6 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Dec 22, 2025 at 1:10 AM#4
newstart_MO said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

8 3wanda_boise, NurseAsh_DET, BenResearch_OR and 5 others
Reply Quote Save Share Report
roxy_nash
Member
178
890
Dec 2024
Nashville, TN
Dec 22, 2025 at 1:01 PM#5

From the other side of the consultation, briefly.

newstart_MO said:
...we're creating a generation dependent on cardiovascular risk...

I understand the concern, but consider this analogy: are we "creating a generation dependent on" blood pressure medication? Cholesterol medication? Thyroid medication?

Obesity is a chronic disease with biological drivers. Treating it with medication is no different from treating any other chronic condition. The "dependency" framing implies weakness or moral failure — neither of which is accurate.

If ongoing medication is what keeps someone healthy, that's successful treatment, not dependency.

Last edited: Dec 22, 2025 at 7:01 PM
7 2kim_atl_prep, sarah_TO, wendy_avl and 4 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register